"The ultimate read-out for this program will be conducted in primary cells (cells derived directly from a living organism rather than the immortalised laboratory cells used here) and will demonstrate the absolute numbers of cells that we are able to successfully achieve gene-editing in relative to alternative delivery approaches (eg. electroporation and lipid-based delivery systems). The primary cells used in this read-out will be the cell type of interest for the ex vivo commercial applications of the CRISPR/Cas9 technology and should therefore directly inform the commercialisation prospects for the program."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)